Table 5 Combination of SNPs with overall grade ≥ 3 toxicity associations in gastric cancer patients treated with platinum/fluoropyridines -based chemotherapy
SNPs combination | Control (n = 61) n (%) | Case (n = 32) n (%) | OR [95% CI] | p-value |
|---|---|---|---|---|
DPYD dom (rs1801265)Â +Â UMPS rec (rs1801019) | ||||
 AA + GG/GC | 38 (63.3) | 9 (29.0) | ref. | – |
 AA + CC | 2 (3.3) | 1 (3.2) | 2.11 (0.09–24.53) | 0.55 |
 AG/GG + GG/GC | 20 (33.3) | 20 (64.5) | 4.22 (1.66–11.40) | 0.0031 |
 AG/GG + CC | 0 (0) | 1 (3.2) | NA | NA |
DPYD dom (rs1801265) + SHMT1 dom (rs1979277) | ||||
 AA + GG | 19 (32.2) | 7 (22.6) | ref. | – |
 AA + GA/AA | 20 (33.9) | 3 (9.7) | 0.40 (0.07–1.69) | 0.23 |
 AG/GG + GG | 10 (16.9) | 12 (38.7) | 3.25 (0.99–11.39) | 0.055 |
 AG/GG + GA/AA | 10 (16.9) | 9 (29.0) | 2.44 (0.70–8.84) | 0.16 |
DPYD dom (rs1801265) + ABCC2 dom (rs717620) | ||||
 AA + CC | 30 (50.0) | 8 (25.8) | ref. | – |
 AA + CT/TT | 10 (16.7) | 2 (6.5) | 0.75 (0.10–3.64) | 0.74 |
 AG/GG + CC | 19 (31.7) | 18 (58.1) | 3.55 (1.32–10.20) | 0.014 |
 AG/GG + CT/TT | 1 (1.7) | 3 (9.7) | 11.25 (1.25–245.45) | 0.047 |